Abstract
The p53 tumor suppressor is regulated by the MDM2 oncoprotein. Overexpression of MDM2 maintains p53 at low levels and contributes to the functional inactivation of p53 in a subset of tumors. We found that treatment with roscovitine and olomoucin, which were originally developed as cyclin-dependent kinase (CDK) inhibitors, can efficiently stabilize and activate nuclear p53 in tumor cells with MDM2 amplification or cytoplasmic p53. These inhibitors block the degradation of p53 without affecting p53-MDM2 binding and the nuclear shuttling function of p53 and MDM2. Roscovitine also induces stabilization of the p53 Ala-315 mutant, indicating that it does not act by regulating the CDK phosphorylation of serine 315. Roscovitine induces down-regulation of MDM2 expression at both protein and mRNA levels. Ectopic expression of MDM2 can abrogate the ability of roscovitine to induce p53 stabilization. Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion. These results show that the small molecule CDK inhibitors can be used to activate p53 through their potent inhibitory effect on MDM2 expression and may be useful as sensitizing agents for other DNA-damaging drugs.
Similar content being viewed by others
References
Addison C, Jenkin JR, Sturzbecher HW . 1990 Oncogene 5: 423–426
Andera L, Wasylyk B . 1997 Mol. Med. 3: 852–863
Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D . 1990 Proc. Natl. Acad. Sci. USA 87: 4766–4770
Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P . 1999 Oncogene 18: 1723–1732
Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, Hupp TR . 2000 Oncogene 19: 3829–3839
Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP . 1997 Curr. Biol. 7: 860–869
Chang D, Chen F, Zhang F, McKay BC, Ljungman M . 1999 Cell Growth. Differ. 10: 155–162
Chehab NH, Malikzay A, Appel M, Halazonetis TD . 2000 Genes. Dev. 14: 278–288
Chen J, Marechal V, Levine AJ . 1993 Mol. Cell Biol. 13: 4107–4114
Chen L, Agrawal S, Zhou W, Zhang R, Chen J . 1998 Proc. Natl. Acad. Sci. USA 95: 195–200
Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J . 1999 Mol. Med. 5: 19–32
Cordon Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ . 1994 Cancer Res. 54: 794–799
David-Pfeuty T, Chakrani F, Ory K, Nouvian-Dooghe Y . 1996 Cell Growth Differ. 7: 1211–1225
Gossen M, Bujard H . 1992 Proc. Natl. Acad. Sci. USA 89: 5547–5551
Hajduch M, Havlieek L, Vesely J, Novotny R, Mihal V, Strnad M . 1999 Adv. Exp. Med. Biol. 457: 341–353
Hall PA, McKee PH, Menage HD, Dover R, Lane DP . 1993 Oncogene 8: 203–207
Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G . 1996 J. Biol. Chem. 271: 29380–29385
Heuvel S, Harlow E . 1993 Science 262: 2050–2054
Hietanen S, Lain S, Krausz E, Blattner C, Lane DP . 2000 Proc. Natl. Acad. Sci. USA 97: 8501–8506
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW . 2000 Science 287: 1824–1827
Juven-Gershon T, Oren M . 1999 Mol. Med. 5: 71–83
Kapoor M, Hamm R, Yan W, Taya Y, Lozano G . 2000 Oncogene 19: 358–364
Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B . 1993 Cancer Res. 53: 2231–2234
Li L, Ljungman M, Dixon JE . 2000 J. Biol. Chem. 275: 2410–2414
Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC . 1999 Oncogene 18: 583–592
Lu H, Taya Y, Ikeda M, Levine AJ . 1998 Proc. Natl. Acad. Sci. USA 95: 6399–6402
Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J . 2000 Oncogene 19: 232–240
McMasters KM, Montes de Oca Luna R, Pena JR, Lozano G . 1996 Oncogene 13: 1731–1736
Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP . 1997 Eur. J. Biochem. 243: 527–536
Meng RD, Shih H, Prabhu NS, George DL, El-Deiry WS . 1998 Clin. Cancer Res. 4: 251–259
Moll UM, Riou G, Levine AJ . 1992 Proc. Natl. Acad. Sci. USA 89: 7262–7266
Moll UM, LaQuaglia M, Benard J, Riou G . 1995 Proc. Natl. Acad. Sci. USA 92: 4407–4411
O'Grady A, Kay EW, McKenna DB, Bennett MA, Murphy GM, Leader MB . 1998 Hum. Pathol. 29: 559–564
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B . 1992 Nature 358: 80–83
Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ . 1998 EMBO J. 17: 554–564
Sankrithi N, Eskin A . 1999 J. Neurochem. 72: 605–613
Schang LM, Rosenberg A, Schaffer PA . 1999 J. Virol. 73: 2161–2172
Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V . 1990 Mol. Cell Biol. 10: 6565–6577
Sherr CJ . 1998 Genes Dev. 12: 2984–2991
Shieh SY, Ahn J, Tamai K, Taya Y, Prives C . 2000 Genes Dev. 14: 289–300
Slingerland JM, Jenkins JR, Benchimol S . 1993 EMBO J. 12: 1029–1037
Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM . 1999 EMBO J. 18: 1660–1672
Tao W, Levine AJ . 1999 Proc. Natl. Acad. Sci. USA 96: 3077–3080
Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S . 1994 Eur. J. Biochem. 224: 771–786
Wang Y, Prives C . 1995 Nature 376: 88–91,
Wu L, Levine AJ . 1997 Mol. Med. 3: 441–451
Wu X, Bayle JH, Olson D, Levine AJ . 1993 Genes Dev. 7: 1126–1132
Acknowledgements
This work was supported by the H. Lee Moffitt Cancer Center and by grants from the National Institutes of Health and the American Cancer Society to J Chen.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lu, W., Chen, L., Peng, Y. et al. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20, 3206–3216 (2001). https://doi.org/10.1038/sj.onc.1204412
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204412
- Springer Nature Limited
Keywords
This article is cited by
-
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
Cell Death & Disease (2020)
-
Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine
BMC Molecular and Cell Biology (2019)
-
Identification of p53-target genes in Danio rerio
Scientific Reports (2016)
-
Inhibitors of the p53-Mdm2 interaction increase programmed cell death and produce abnormal phenotypes in the placozoon Trichoplax adhaerens (F.E. Schulze)
Development Genes and Evolution (2014)
-
Implication of transcriptional repression in compound C-induced apoptosis in cancer cells
Cell Death & Disease (2013)